- Conditions
- Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4, Advanced Breast Cancer, Advanced Lung Carcinoma, NSCLC, NSCLC, Recurrent, NSCLC Stage IV, Relapsed Cancer, Relapse/Recurrence, Recurrent Breast Cancer, Recurrent NSCLC, Platinum-resistant Ovarian Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Endometrioid Tumor, High Grade Serous Carcinoma, Ovarian Epithelial Cancer
- Interventions
- Not listed
- Lead sponsor
- Lyell Immunopharma, Inc.
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Rocky Mount, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1489–1512
of 1,764
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Solid Tumor Malignancies, Metastatic Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer, Bladder Cancer
- Interventions
- Expert Review, Blood or tissue samples collection., The Precision Oncology Navigation
- Other
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Metastatic Solid Tumors
- Interventions
- aldoxorubicin, gemcitabine
- Drug
- Lead sponsor
- ImmunityBio, Inc.
- Industry
- Eligibility
- 15 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • Santa Monica, California
- Conditions
- Metastatic Cancer, Solid Tumor, Head and Neck Cancer
- Interventions
- LYT-200, Tislelizumab
- Drug
- Lead sponsor
- PureTech
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Denver, Colorado • Sarasota, Florida + 7 more
- Conditions
- Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm
- Interventions
- Arginine, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Spectroscopy, Whole-Brain Radiotherapy
- Drug · Procedure · Radiation
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Metastatic Cancer
- Interventions
- Keytruda Injectable Product, Yervoy Injectable Product, GM-CSF, Non-ablative Cryosurgical freezing
- Drug · Procedure
- Lead sponsor
- ImmunSYS, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • Miami Lakes, Florida
- Conditions
- Advanced Breast Cancer (Parts 1 and 2), Advanced Pancreatic Cancer (Part 1), Advanced Colorectal Cancer (Part 1), Advanced Cholangiocarcinoma (Part 1), Advanced Glioblastoma Multiforme (Part 1)
- Interventions
- Bosutinib, Capecitabine
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Detroit, Michigan
- Conditions
- Biliary Tract Cancer (BTC), Colorectal Cancer (CRC), Endometrial Cancer, Gastroesophageal Cancer (GC), Ovarian Cancer, Solid Tumors
- Interventions
- INCB001158, Oxaliplatin, Leucovorin, 5-Fluorouracil, Gemcitabine, Cisplatin, Paclitaxel
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 149 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Sacramento, California + 3 more
- Conditions
- Advanced Solid Tumors
- Interventions
- ASP1002, Bevacizumab, Oxaliplatin, Leucovorin, Fluorouracil, Irinotecan, Trifluridine-Tipiracil, Pembrolizumab, Pemetrexed, Carboplatin, Ramucirumab, Docetaxel
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 798 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 15
- States / cities
- New Haven, Connecticut • Plainville, Connecticut • Gainesville, Florida + 11 more
- Conditions
- Non Small Cell Lung Cancer Squamous (NSCLC-Sq), Head and Neck Squamous Cell Carcinoma (HNSCC), Small Cell Lung Cancer (SCLC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC), Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Interventions
- MEDI7247
- Drug
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 101 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 2
- States / cities
- Huntersville, North Carolina • Nashville, Tennessee
- Conditions
- Cancer, Solid Tumor, Colorectal Cancer, Pancreas Cancer, Non Small Cell Lung Cancer, Head and Neck Cancer, Gynecologic Cancer, Skin Cancer, Kidney Cancer
- Interventions
- DK210 (EGFR), Radiation therapy, Immune checkpoint blockers, Chemotherapy
- Biological · Radiation · Drug
- Lead sponsor
- DEKA Biosciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 7
- States / cities
- Duarte, California • Manhasset, New York • Oklahoma City, Oklahoma + 3 more
- Conditions
- Metastatic Solid Cancers, Colorectal Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Gastrointestinal Cancer, Ovarian Cancer, Genitourinary Cancer
- Interventions
- Aldesleukin, Fludarabine, Cyclophosphamide, KRAS TCR-Transduced PBL, GRT-C903/GRT-R904
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 72 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Metastatic Solid Tumors, Stage 4 Cancer
- Interventions
- The Sarah Nanotechnology System - intended to deliver thermal energy to malignant cells for the purpose of thermal destruction of these cells in patients with advanced metastatic solid tumors.
- Device
- Lead sponsor
- New Phase Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Metastatic Biliary Tract Carcinoma, Metastatic Colon Carcinoma, Metastatic Esophageal Carcinoma, Metastatic Malignant Digestive System Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Carcinoma, Stage IV Colon Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
- Interventions
- Biospecimen Collection, Computed Tomography, Pemetrexed, PRMT5 Inhibitor BMS-986504
- Procedure · Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
- Interventions
- Neratinib, Fulvestrant, Trastuzumab, Paclitaxel
- Drug
- Lead sponsor
- Puma Biotechnology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 582 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2023
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 26 more
- Conditions
- Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC, Esophageal Cancer, Gastric Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma (PDAC), Cervical Cancer, Endometrial Cancer, Urothelial Cancer
- Interventions
- STRO-004, Pembrolizumab
- Drug
- Lead sponsor
- Sutro Biopharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 9
- States / cities
- San Diego, California • Denver, Colorado • Washington D.C., District of Columbia + 6 more
- Conditions
- Locally Advanced/Metastatic HER2 Positive Solid Tumors
- Interventions
- BB-1701
- Drug
- Lead sponsor
- Bliss Biopharmaceutical (Hangzhou) Co., Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 3
- States / cities
- San Francisco, California • Nashville, Tennessee • Fairfax, Virginia
- Conditions
- Solid Tumors
- Interventions
- Atezolizumab, RO6958688
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 228 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 11
- States / cities
- Santa Monica, California • Stanford, California • Aurora, Colorado + 7 more
- Conditions
- Solid Tumour
- Interventions
- PHA-848125AC
- Drug
- Lead sponsor
- Nerviano Medical Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • Baltiomore, Maryland
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Cutaneous Melanoma, Locally Advanced Mucosal Melanoma, Metastatic Acral Melanoma, Metastatic Conjunctival Melanoma, Metastatic Cutaneous Melanoma, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Mucosal Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Recurrent Cutaneous Melanoma, Recurrent HER2-Negative Breast Carcinoma, Recurrent Hormone Receptor-Positive Breast Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Mucosal Melanoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Unresectable Acral Melanoma, Unresectable Cutaneous Melanoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Mucosal Melanoma
- Interventions
- Neoantigen Peptide Vaccine, Nivolumab, Poly ICLC, Echocardiography Test, Multigated Acquisition Scan, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Ruxolitinib
- Biological · Drug · Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Neoplasms
- Interventions
- Regorafenib (Stivarga, BAY73-4506), Cetuximab (ERBITUX)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Aurora, Colorado • St Louis, Missouri + 1 more
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- bortezomib, paclitaxel, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Venous Thromboembolism (VTE)
- Interventions
- REGN7508, Apixaban
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 3
- States / cities
- Hialeah, Florida • New York, New York • El Paso, Texas
- Conditions
- Solid Tumors
- Interventions
- CEP-37440
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Philadelphia, Pennsylvania • San Antonio, Texas